HSP90 Inhibitors for Neurodegeneration

HSP90 Inhibitors in Neurodegeneration

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">HSP90 Inhibitors for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Structure</td>
<td>Homodimer, each monomer ~90 kDa</td>
</tr>
<tr>
<td class="label">ATPase Cycle</td>
<td>ATP binding → conformational change → hydrolysis → client protein folding</td>
</tr>
<tr>
<td class="label">Client Proteins</td>
<td>~200 known, including kinases, transcription factors, receptors</td>
</tr>
<tr>
<td class="label">Co-chaperones</td>
<td>Hsp70, Hsp40, Hop, CHIP, p23</td>
</tr>
<tr>
<td class="label">Class</td>
<td>Synthetic small molecule</td>
</tr>
<tr>
<td class="label">Target</td>
<td>HSP90 (N-terminal)</td>
</tr>
<tr>
<td class="label">Affinity</td>
<td>IC50 ~ 2 nM</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Clinical trials in oncology; preclinical in neurodegeneration</td>
</tr>
<tr>
<td class="label">Class</td>
<td>Natural product derivative</td>
</tr>
<tr>
<td class="label">Target</td>
<td>HSP90</td>
</tr>
<tr>
<td class="label">Affinity</td>
<td>IC50 ~ 20-65 nM</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Preclinical; clinical trials in oncology</td>
</tr>
<tr>
<td class="label">Class</td>
<td>Natural product derivative</td>
</tr>
<tr>
<td class="label">Target</td>
<td>HSP90</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Clinical trials in oncology</td>

...

HSP90 Inhibitors in Neurodegeneration

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">HSP90 Inhibitors for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Structure</td>
<td>Homodimer, each monomer ~90 kDa</td>
</tr>
<tr>
<td class="label">ATPase Cycle</td>
<td>ATP binding → conformational change → hydrolysis → client protein folding</td>
</tr>
<tr>
<td class="label">Client Proteins</td>
<td>~200 known, including kinases, transcription factors, receptors</td>
</tr>
<tr>
<td class="label">Co-chaperones</td>
<td>Hsp70, Hsp40, Hop, CHIP, p23</td>
</tr>
<tr>
<td class="label">Class</td>
<td>Synthetic small molecule</td>
</tr>
<tr>
<td class="label">Target</td>
<td>HSP90 (N-terminal)</td>
</tr>
<tr>
<td class="label">Affinity</td>
<td>IC50 ~ 2 nM</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Clinical trials in oncology; preclinical in neurodegeneration</td>
</tr>
<tr>
<td class="label">Class</td>
<td>Natural product derivative</td>
</tr>
<tr>
<td class="label">Target</td>
<td>HSP90</td>
</tr>
<tr>
<td class="label">Affinity</td>
<td>IC50 ~ 20-65 nM</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Preclinical; clinical trials in oncology</td>
</tr>
<tr>
<td class="label">Class</td>
<td>Natural product derivative</td>
</tr>
<tr>
<td class="label">Target</td>
<td>HSP90</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Clinical trials in oncology</td>
</tr>
<tr>
<td class="label">Class</td>
<td>Purine scaffold</td>
</tr>
<tr>
<td class="label">Target</td>
<td>HSP90 (selective)</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Clinical trials in oncology; preclinical in neurodegeneration</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Class</td>
</tr>
<tr>
<td class="label">NVP-HSP990</td>
<td>Synthetic</td>
</tr>
<tr>
<td class="label">KW-2478</td>
<td>Synthetic</td>
</tr>
<tr>
<td class="label">AT13387</td>
<td>Synthetic</td>
</tr>
<tr>
<td class="label">XL888</td>
<td>Synthetic</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Model</td>
</tr>
<tr>
<td class="label">Ganetespib</td>
<td>3xTg AD mice</td>
</tr>
<tr>
<td class="label">17-AAG</td>
<td>[APP](/entities/app-protein)/PS1 mice</td>
</tr>
<tr>
<td class="label">PU-H71</td>
<td>Tauopathy models</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Model</td>
</tr>
<tr>
<td class="label">Ganetespib</td>
<td>α-synuclein models</td>
</tr>
<tr>
<td class="label">17-DMAG</td>
<td>MPTP model</td>
</tr>
<tr>
<td class="label">17-AAG</td>
<td>α-synuclein tg mice</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Model</td>
</tr>
<tr>
<td class="label">17-DMAG</td>
<td>SOD1 mice</td>
</tr>
<tr>
<td class="label">Ganetespib</td>
<td>[TDP-43](/proteins/tdp-43) models</td>
</tr>
<tr>
<td class="label">17-AAG</td>
<td>SOD1 G93A mice</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Model</td>
</tr>
<tr>
<td class="label">17-DMAG</td>
<td>R6/2 mice</td>
</tr>
<tr>
<td class="label">Ganetespib</td>
<td>Cell models</td>
</tr>
<tr>
<td class="label">HSP90 inhibitors</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>Compound</td>
</tr>
<tr>
<td class="label">Frontotemporal Dementia</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Prion Disease</td>
<td>17-AAG</td>
</tr>
<tr>
<td class="label">Multiple System Atrophy</td>
<td>Ganetespib</td>
</tr>
</table>

Introduction

Hsp90 Inhibitors For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

HSP90 (Heat Shock Protein 90) inhibitors represent a promising therapeutic strategy for neurodegenerative diseases by targeting proteostasis dysfunction, a hallmark of disorders characterized by misfolded protein accumulation. HSP90 is a molecular chaperone that plays a critical role in folding, stabilization, and quality control of numerous client proteins, including many implicated in neurodegeneration. By inhibiting HSP90, these compounds promote the clearance of toxic protein aggregates through the proteasome and autophagy pathways. [@dickey2007]

Background: The HSP90 Chaperone System

HSP90 Biology

HSP90 is an abundant cytosolic chaperone (1-2% of total cellular protein) essential for cellular proteostasis: [@chen2011]

HSP90 in Neurodegeneration

In neurodegenerative diseases, HSP90 plays a paradoxical role:

Protective Function

• Helps refold misfolded proteins
• Targets damaged proteins for degradation
• Maintains proteostasis

Pathogenic Function

• Stabilizes mutant proteins (mutant [huntingtin](/proteins/huntingtin-protein), [α-synuclein](/proteins/alpha-synuclein), tau)
• Prevents degradation of toxic oligomers
• Facilitates aggregation in some contexts

The HSP90 Inhibitor Rationale

HSP90 inhibitors shift the equilibrium toward protein degradation:

• Inhibition causes client protein destabilization
• Misfolded proteins are recognized by the proteasome
• Heat shock response is activated (HSF1)
• Overall enhancement of proteostasis

Mechanism of Action

Primary Mechanisms

ATPase Inhibition

• HSP90 requires ATP for its chaperone cycle
• Inhibitors bind the N-terminal ATP-binding pocket
• Prevents proper protein folding
• Client proteins are released in misfolded state

Client Protein Degradation

• Misfolded proteins are ubiquitinated
• Targeted for proteasomal degradation
• [Autophagy](/entities/autophagy) may also be engaged

Heat Shock Response Activation

• HSP90 inhibition releases HSF1 (Heat Shock Factor 1)
• HSF1 translocates to nucleus
• Induces expression of protective chaperones (Hsp70, Hsp40)
• Creates beneficial proteostasis environment

Secondary Mechanisms

• Immunomodulation — Reduces neuroinflammation
• Mitochondrial protection — Improves mitochondrial function
• Synaptic preservation — Maintains synaptic protein levels

Key Therapeutic Compounds

Ganetespib (STA-9090)

Key features:

• Highly potent HSP90 inhibitor
• Resorcinol-based structure
• Demonstrated in AD, PD, ALS models

17-DMAG (Alvespimycin)

Key features:

• Geldanamycin derivative
• Has shown activity in ALS and HD models

17-AAG (Tanespimycin)

Key features:

• First-generation HSP90 inhibitor
• Has been tested in AD models

PU-H71

Key features:

• Purine-based structure
• Good brain penetration
• Active in models of tauopathy

Other Compounds

Clinical Evidence by Disease

Alzheimer's Disease

Mechanisms:

• Promotes [BACE1](/entities/bace1) degradation (reduces [Aβ](/proteins/amyloid-beta) production)
• Enhances tau clearance
• Activates HSF1 and protective chaperones

Parkinson's Disease

Mechanisms:

• Promotes α-synuclein clearance
• Protects substantia nigra neurons
• Reduces oligomer formation

Amyotrophic Lateral Sclerosis

Mechanisms:

• Promotes mutant SOD1 clearance
• Reduces TDP-43 aggregation
• Protects motor neurons

Huntington's Disease

Mechanisms:

• Promotes mutant huntingtin degradation
• Activates HSF1 and Hsp70
• Improves striatal neuron survival

Other Disorders

Combination Strategies

HSP90 inhibitors may be combined with:

Autophagy Enhancers

• [mTOR](/entities/mtor) inhibitors (rapamycin)
• Trehalose
• Natural compounds (resveratrol)

Proteasome Modulators

• Subtle proteasome enhancement
• Avoid complete inhibition

Histone Deacetylase (HDAC) Inhibitors

• May enhance chaperone expression
• Synergistic proteostasis effects

Other Chaperones

• Hsp70 inducers
• Hsp40 co-chaperones

Challenges and Limitations

Toxicity Concerns

Heat Shock Response Side Effects

• HSP90 inhibition in peripheral tissues
• Liver enzyme elevations
• Gastrointestinal effects

On-target Effects

• IGF-1R and other client depletion
• Fatigue, weight loss

Pharmacological Challenges

Brain Penetration

• Some compounds have limited [BBB](/entities/blood-brain-barrier) entry
• P-glycoprotein efflux
• Need for brain-penetrant derivatives

Therapeutic Window

• Must balance client degradation with toxicity
• Dose optimization critical

Client Protein Specificity

• HSP90 has many clients
• May affect both pathological and physiological proteins
• Need for selective targeting

Research Directions

Novel Approaches

Selective Brain-Penetrant Inhibitors

• PU-H71 showed promise
• New derivatives in development

Allosteric Inhibitors

• C-terminal HSP90 inhibitors
• Different mechanism, potentially reduced toxicity

Proteostasis Modulation

• Broader proteostasis approach
• Combining with autophagy enhancers

Combination Therapies

• HSP90 inhibitors + autophagy inducers
• HSP90 inhibitors + immunotherapy

Biomarkers

• Client protein levels in CSF
• Hsp70 induction markers
• Imaging of protein aggregates

Summary

HSP90 inhibitors offer a unique approach to neurodegenerative disease by enhancing proteostasis through modulation of the chaperone system. By inhibiting HSP90, these compounds promote the clearance of toxic protein aggregates (Aβ, tau, α-synuclein, mutant huntingtin, TDP-43) while activating protective heat shock responses. Ganetespib, PU-H71, and 17-DMAG have shown promising results in preclinical models of AD, PD, ALS, and HD. Key challenges include brain penetration, therapeutic window optimization, and managing on-target toxicity. The field is moving toward combination approaches that enhance proteostasis through multiple mechanisms.

See Also

• [Autophagy Enhancers](/therapeutics/autophagy-enhancers-pd)
• [Protein Homeostasis Pathway](/mechanisms/dopaminergic-neuron-vulnerability)
• [Heat Shock Response](/mechanisms/dopaminergic-neuron-vulnerability)
• [Unfolded Protein Response](/mechanisms/endoplasmic-reticulum-stress-neurodegeneration)
• [Proteasome Modulators](/mechanisms/dopaminergic-neuron-vulnerability)
• [Alzheimer's Disease Treatment Overview](/therapeutics/overview)
• [Parkinson's Disease Treatment Overview](/therapeutics/parkinson-treatment)

External Links

• [ClinicalTrials.gov - HSP90 Inhibitors](https://clinicaltrials.gov/search?cond=Alzheimer+disease&intr=HSP90+inhibitor)
• [PubMed - HSP90 Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=HSP90+inhibitor+neurodegeneration+Alzheimer)
• [CSP90 Biology - Cell](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004490/)

References

[Luo W, Sun W, Taldone T, et al, Heat shock protein 90 in neurodegenerative diseases (2010)](https://pubmed.ncbi.nlm.nih.gov/20550756/)

[Dickey CA, Kamal A, Lundgren K, et al, The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau clients (2007)](https://pubmed.ncbi.nlm.nih.gov/17215396/)

[Chen Y, Chen J, Wu J, et al, Heat shock protein 90 inhibitor reduces α-synuclein aggregation and cytotoxicity in models of Parkinson's disease (2011)](https://pubmed.ncbi.nlm.nih.gov/21397062/)

Waza M, Adachi H, Katsuno M, et al, 17-DMAG ameliorates polyglutamine-mediated motor neuron degeneration through atrogenen and HSP90 expression (2005)

Fujikake N, Nagai Y, Popiel HA, et al, Heat shock protein 90 inhibitor and neurodegeneration (2008)

Luo W, Dou F, Ruan Y, et al, Roles of heat-shock protein 90 in neuronal Ca2+ signaling and learning and memory (2007)

Shim JS, Yang JW, Kwon H, et al, Dual targeting of HSP90 and HO-1 as a novel therapeutic strategy for neurodegenerative diseases (2023)

Balchin D, Hayer-Hartl M, Hartl FU, In vivo aspects of the Hsp90 chaperone (2016)

Trepel J, Mollapour M, Giaccone G, et al, Targeting the dynamic HSP90 complex in cancer (2010)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
• [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
• [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
• [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7

Related Analyses:

• [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) &#x1f504;
• [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;